7.26

2.40% 0.17

After Hours: 7.18 -0.08 -1.10%

Mannkind Corp (MNKD)

Overview News Price History Option Chain Financials Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is traded at $7.26, with a volume of 1.75M. It is up +2.40% in the last 24 hours and up +11.86% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Previous Close:

$7.09

Open:

$7.02

24h Volume:

1.75M

Relative Volume:

0.75

Market Cap:

$2.00B

Revenue:

$248.37M

Net Income/Loss:

$11.74M

P/E Ratio:

-38.21

EPS:

-0.19

Net Cash Flow:

$18.24M

1W Performance:

+5.68%

1M Performance:

+11.86%

6M Performance:

+65.38%

1Y Performance:

+83.33%

1-Day Range:

$7.01

$7.30

1-Week Range:

$6.7745

$7.325

52-Week Range:

$3.17

$7.325

Mannkind Corp Stock (MNKD) Company Profile

Name

Mannkind Corp

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

818-661-5000

Address

1 CASPER STREET, DANBURY, CA

Employee

414

Twitter

@MannKindCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

MNKD's Discussions on Twitter

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-23	Initiated	Wedbush	Outperform
May-14-21	Initiated	RBC Capital Mkts	Sector Perform
Dec-24-19	Initiated	Oppenheimer	Outperform
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight
May-14-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	SVB Leerink	Outperform
Feb-22-19	Initiated	SVB Leerink	Outperform
Feb-28-18	Downgrade	Maxim Group	Hold → Sell
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Reiterated	Maxim Group	Buy
Aug-11-17	Initiated	Maxim Group	Buy
May-10-16	Reiterated	Piper Jaffray	Underweight
May-10-16	Reiterated	RBC Capital Mkts	Underperform
Jan-06-16	Reiterated	Piper Jaffray	Underweight
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform
May-11-15	Downgrade	JP Morgan	Neutral → Underweight
May-11-15	Reiterated	MLV & Co	Hold
Apr-16-15	Reiterated	RBC Capital Mkts	Outperform

View All

Mannkind Corp Stock (MNKD) Latest News

Nov 04, 2024

MannKind (NASDAQ:MNKD) Reaches New 1-Year HighHere's What Happened - MarketBeat

Nov 04, 2024

Nov 02, 2024

MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN

Nov 02, 2024

Nov 01, 2024

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - ForexTV.com

Oct 31, 2024

Oct 29, 2024

MannKind (NASDAQ:MNKD) Sets New 1-Year HighTime to Buy? - MarketBeat

Oct 29, 2024

MannKind stock soars to 52-week high, touches $6.93 - Investing.com

Oct 29, 2024

Oct 17, 2024

MannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 17, 2024

Oct 16, 2024

MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results - AOL

Oct 16, 2024

SG Americas Securities LLC Takes Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat

Oct 16, 2024

Oct 15, 2024